Alex Zhavoronkov, CEO of Insilico Medicine, lifts the lid on the role of AI in target discovery, identification, and validation. He also offers his opinion on the future of innovative drug development in China, and the challenges of establishing a biotech company in Hong Kong.
Our research within AI does not stop. We have new systems that can generate biological data indistinguishable from real biological data and can now imagine high-quality human data
Alex Wong, CEO of Xcelom sat down with PharmaBoardroom to discuss the company’s non-invasive prenatal testing (NIPT) technology and increasing capacity in the field of screening for chromosomal disorders. Wong…
Dr Desmond Hau, CEO of Pangenia Inc, sits down with PharmaBoardroom to shed light on the company’s progress since taking the reins three years ago. Hau also explains Pangenia’s strategy…
Dr Albert Yu, chairman of the Hong Kong Biotechnology Organization (HKBIO) gives his expert insights into the crucial importance of diagnostics in countering the COVID-19 pandemic, how Hong Kong’s positioning…
Despite a “turbulent macro backdrop,” the strong momentum in Hong Kong’s IPO market has continued in the third quarter of 2021, driven to a large extent by new biotech listings.…
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its own mRNA vaccine; an update on Hong Kong’s biotech investment ecosystem three year…
Three years after the Hong Kong Stock Exchange (HKEX) introduced reforms to allow and support the listing of pre-profit biotech companies, it has become Asia’s largest, and the world’s second-largest,…
See our Cookie Privacy Policy Here